The molecular mechanism of spleen-strengthening and moisture-nourishing liver prescription in treatment of acute-on-chronic liver failure based on network pharmacology and experimental verification

Qi HUANG; Wen-Feng MA; Zhi-Yi HAN; Jia-Ling SUN; Wei ZHANG; Xin-Feng SUN; Jian -Ping CHEN; Xiao-Zhou ZHOU; Qi HUANG; Wen-Feng MA; Zhi-Yi HAN; Jia-Ling SUN; Wei ZHANG; Xin-Feng SUN; Xiao-Zhou ZHOU; Jing LI; Xiao-Zhou ZHOU; Jian -Ping CHEN

Return

The molecular mechanism of spleen-strengthening and moisture-nourishing liver prescription in treatment of acute-on-chronic liver failure based on network pharmacology and experimental verification

Author: Qi HUANG ¹ ; Wen-Feng MA ¹ ; Zhi-Yi HAN ¹ ; Jia-Ling SUN ¹ ; Wei ZHANG ¹ ; Xin-Feng SUN ¹ ; Jian -Ping CHEN ¹ ; Xiao-Zhou ZHOU ¹ ; Qi HUANG ² ; Wen-Feng MA ² ; Zhi-Yi HAN ² ; Jia-Ling SUN ² ; Wei ZHANG ² ; Xin-Feng SUN ² ; Xiao-Zhou ZHOU ² ; Jing LI ³ ; Xiao-Zhou ZHOU ³ ; Jian -Ping CHEN ⁴
Author Information

1. School of Fourth Clinical Medicine, Guangzhou University of Chinese Medicine
2. National Key Specialty of Clinical Liver Disease (Traditional Chinese Medicine) of Shenzhen Traditional Chinese Medicine Hospital
3. School of Chinese Medicine, Macau University of Science and Technology
4. Key Laboratory of Traditional Chinese Medicine Formulation Research, Shenzhen Traditional Chinese Medicine Hospital
Publication Type:Journal Article
Keywords: acute-on-chronic liver failure; molecular docking; network pharmacology; quercetin; signaling pathway; spleen-strengthening and moisture-nouristhing liver prescription
From: Chinese Pharmacological Bulletin 2024;40(3):557-564
CountryChina
Language:Chinese
Abstract: To explore the mechanism of spleen- were obtained for the treatment of acute-on-chronic livstrengthening and moisture-nourishing liver prescription er failure, and 244 intersecting target genes and 7 core (JPLSYGF) in the treatment of acute-on-chronic liver target genes were screened. Molecular docking showed failure using network pharmacology and the molecular that the core target genes AKT1, SRC, VEGFA, docking. Methods Relying on TCMSP and Gene- STAT3 , EGFR, MAPK3 , HRAS had good affinity with Cards and other databases, the relevant targets of JPL- quercetin, the main active component in the JPLSYGF in the treatment of acute-on-chronic liver failure SYGF, and had strong binding activity. In addition, in were obtained. String and Cytoscape were used to con- vivo tests verified that the JPLSYGF could reduce the struct PPI networks of targets, core targets were expression of HRAS, EGFR, STAT3 , SRC, and VEGscreened out, and DAVID was used for GO function FA, to delay the progression of acute-on-chronic liver annotation and KEGG pathway enrichment analysis. failure. Conclusions JPLSYGF may act on core tar- The main active ingredients of the traditional Chinese gets such as HRAS, EGFR, STAT3, SRC, VEGFA medicine compound formula for JPLSYGF were select- and so on, to achieve the effect of treating acute-oned with a bioavailability OB value of =Э 30% and a chronic liver failure. drug-like DL^O. 18 as the screening conditions, and.